In Phase A, participants will get different doses and schedules of oral ABBV-744 tablet to establish Protected dosing program. Extra individuals will be enrolled with the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. In Section https://abbv-744combinationtherap46891.ampedpages.com/5-easy-facts-about-is-abbv-744-effective-for-hematologic-cancers-described-59128633